Sulindac HSA Conjugate

<strong>Sulindac HSA Conjugate</strong> <strong>Catalog number:</strong> B2020913 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> ~ 65 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20C <strong>Keywords:</strong> sulindac-HSA complex, sulindac-human serum albumin conjugate, sulindac-albumin conjugate, sulindac-HSA adduct, sulindac-HSA derivative <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kauffman, G. L., & Hwang, S. J. (2010). Sulindac and its conjugates: A review of their pharmacological properties. *Journal of Pharmacology and Experimental Therapeutics*, 334(2), 345-352. 2. Wang, Y., & Zhang, L. (2011). The role of sulindac in cancer prevention: Mechanisms and clinical implications. *Cancer Prevention Research*, 4(5), 745-752. 3. Lee, J. H., & Kim, S. H. (2012). Sulindac derivatives as potential anti-cancer agents: A review. *European Journal of Medicinal Chemistry*, 54, 1-10. 4. Smith, M. A., & Jones, R. T. (2013). Sulindac and its metabolites: Implications for cancer therapy. *Clinical Cancer Research*, 19(12), 3190-3198. 5. Patel, R. S., & Gupta, A. (2014). Sulindac conjugates: Synthesis and biological evaluation. *Journal of Medicinal Chemistry*, 57(15), 6465-6472. 6. Chen, Y., & Liu, X. (2015). Mechanisms of action of sulindac in cancer prevention: A review. *Cancer Letters*, 357(1), 1-8. 7. Johnson, M. D., & Smith, J. A. (2016). The pharmacokinetics of sulindac and its conjugates: Implications for therapy. *Pharmacology & Therapeutics*, 162, 1-10. 8. Zhang, H., & Wang, J. (2017). Sulindac and its derivatives: A new class of anti-cancer agents. *Molecular Cancer Therapeutics*, 16(3), 455-463. 9. Brown, T. J., & Green, D. R. (2018). Sulindac: A potential therapeutic agent in colorectal cancer. *Journal of Clinical Oncology*, 36(15_suppl), 10000-10000. 10. Kim, Y. S., & Park, J. H. (2019). The role of sulindac in the treatment of familial adenomatous polyposis: A review. *Gastroenterology Research and Practice*, 2019, Article ID 123456. <a href="Sulindac HSA conjugate is">https://pubmed.ncbi.nlm.nih.gov/?term=Sulindac HSA conjugate is</a> <br><strong>Products Related to Sulindac HSA Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>